Description
Product Properties
|
Property Name |
Property Details |
|
Alternative Names |
CD8A&CD8B (CD8 αβ heterodimer) |
|
Species |
Human |
|
Expression Sequence |
Ser22-Asp182 (CD8 α acidic tail) & Leu22-Pro170 (CD8 β basic tail) |
|
Accession |
P01732-1 (CD8 α) & P10966-1 (CD8 β) |
|
Tag |
C-His-Flag |
|
Expression System |
HEK293 |
|
Molecular Weight |
Predicted MW: 23.54 kDa (CD8 α), 22.62 kDa (CD8 β). Glycosylation shifts migration to 26-28 kDa (CD8 α) and 28-32 kDa (CD8 β) (SDS-PAGE). |
|
Purity |
>95% (SDS-PAGE & HPLC). |
|
Endotoxin |
<1.0 EU/μg (LAL method). |
|
Formulation |
Lyophilized from 0.22 μm filtered PBS (pH 7.4). 8% trehalose added as protectant. |
|
Appearance |
Lyophilized Powder |
|
Biological Activity |
【ELISA Data】 Immobilized Human CD8A&CD8B, His Tag at 0.5 μg/mL (100 μL/well). Dose response curve for Anti-CD8 Antibody (hFc Tag) shows EC₅₀ = 15.2 ng/mL. |
|
Reconstitution Method |
Centrifuge before opening. Reconstitute with distilled water to >100 μg/mL. Aliquot to avoid repeated freeze-thaw cycles. |
Features
High purity, high activity, low endotoxin, high batch-to-batch consistency
Storage
Lyophilized powder: Store at -25 to -15°C; stable for 1 year upon receipt.
Reconstituted protein: Store under sterile conditions at -85 to -65°C; stable for 3 months.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.
Inquiry
You may also like
FAQ
The product is for research purposes only and is not intended for therapeutic or diagnostic use in humans or animals. Products and content are protected by patents, trademarks, and copyrights owned by Yeasen Biotechnology. Trademark symbols indicate the country of origin, not necessarily registration in all regions.
Certain applications may require additional third-party intellectual property rights.
Yeasen is dedicated to ethical science, believing our research should address critical questions while ensuring safety and ethical standards.